News Image

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

Provided By GlobeNewswire

Last update: Jul 1, 2025

-- Milestone expands global reach and reinforces commitment to accessible, first-line infertility solutions --

ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products announces the achievement of regulatory approvals in Australia and New Zealand for its next-generation infertility solutions: FemaSeed® for first-line intratubal insemination treatment and FemVue® for diagnostic evaluation.

Read more at globenewswire.com

FEMASYS INC

NASDAQ:FEMY (7/30/2025, 1:54:55 PM)

0.8323

-0.01 (-0.7%)



Find more stocks in the Stock Screener

Follow ChartMill for more